Correlation Between Protalix Biotherapeutics and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Protalix Biotherapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Blueprint Medicines.
Diversification Opportunities for Protalix Biotherapeutics and Blueprint Medicines
0.46 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Protalix and Blueprint is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Protalix Biotherapeutics and Blueprint Medicines
Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 2.15 times more return on investment than Blueprint Medicines. However, Protalix Biotherapeutics is 2.15 times more volatile than Blueprint Medicines Corp. It trades about 0.33 of its potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.18 per unit of risk. If you would invest 117.00 in Protalix Biotherapeutics on September 1, 2024 and sell it today you would earn a total of 55.00 from holding Protalix Biotherapeutics or generate 47.01% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Protalix Biotherapeutics vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Protalix Biotherapeutics |
| Blueprint Medicines Corp |
Protalix Biotherapeutics and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Protalix Biotherapeutics and Blueprint Medicines
The main advantage of trading using opposite Protalix Biotherapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Complementary Tools
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |